Amylyx Pharmaceuticals, Inc. (AMLX) stock
AMLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$29.86−1.94 (-6.10%)
Close on Nov 12, 2026Market cap $3.33BP/E –Yield –
Amylyx Pharmaceuticals profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Amylyx Pharmaceuticals's profit margin for the twelve months ending Sep 30, 2024 was -132.1%. For fiscal 2024 it was -345.4%, against 12.9% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -345.4% | −358.3 |
| FY2023 | Dec 31, 2023 | 12.9% | +905.3 |
| FY2022 | Dec 31, 2022 | -892.4% | +29960.6 |
| FY2021 | Dec 31, 2021 | -30853.0% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2024 | Sep 30, 2024 | -17476.9% | −17499.4 |
| Q1 FY2024 | Mar 31, 2024 | -134.0% | −136.2 |
| Q4 FY2023 | Dec 31, 2023 | 4.4% | +199.5 |
| Q3 FY2023 | Sep 30, 2023 | 20.3% | +15601.8 |
| Q2 FY2023 | Jun 30, 2023 | 22.5% | +8142.5 |
| Q1 FY2023 | Mar 31, 2023 | 2.2% | – |
| Q4 FY2022 | Dec 31, 2022 | -195.1% | – |
| Q3 FY2022 | Sep 30, 2022 | -15581.4% | – |
| Q3 FY2021 | Sep 30, 2021 | -8120.0% | – |
See a number that looks wrong?